TCC1727 not checked

Beijing Tide Pharmaceutical Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.”In the company’s words, NCT05970016 on ClinicalTrials.gov
Tested for
Patients with Advanced Solid Tumors, Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer, Malignant Melanoma
Main trialPhase 1/2
“This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.”In the company’s words, NCT05970016 on ClinicalTrials.gov

Other drugs for Patients with Advanced Solid Tumors

All 302 drugs for Patients with Advanced Solid Tumors

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 30 Jul 2025 A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
Phase 1/2Recruiting 30 Sep 2028 An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TCC1727

Following is part of Solo: you see every change to TCC1727 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in